Novo Nordisk
NVO
511 hedge funds and large institutions have $7.76B invested in Novo Nordisk in 2016 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 190 increasing their positions, 187 reducing their positions, and 54 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 187
0.86% less ownership
Funds ownership: 19.42% → 18.56% (-0.86%)
3% less funds holding
Funds holding: 529 → 511 (-18)
22% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 54
26% less capital invested
Capital invested by funds: $10.5B → $7.76B (-$2.76B)
42% less funds holding in top 10
Funds holding in top 10: 24 → 14 (-10)
51% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $29M
Top Buyers
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$165M |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$92.2M |
| 3 |
Renaissance Technologies
New York
|
+$84.5M |
| 4 |
Morgan Stanley
New York
|
+$70.2M |
| 5 |
Millennium Management
New York
|
+$67.6M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$545M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$329M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$160M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$103M |
| 5 |
Lazard Asset Management
New York
|
-$78.6M |
NVO Hedge Fund Activity: Q3 2016 in Review
511 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2016, worth a combined $7.76B — down 26% from $10.5B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of NVO and 42 opened new positions — a net loss of 12 holders — while 187 trimmed existing stakes and 190 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $165M. The largest seller was Jennison Associates, cutting an estimated $545M.
- 511 institutional investors held Novo Nordisk (NVO) as of Q3 2016, down from 529 in Q2 2016.
- Funds reported $7.76B of Novo Nordisk stock for Q3 2016, down 26% quarter-over-quarter.
- 42 funds opened new Novo Nordisk positions in Q3 2016 and 54 closed out, a net change of -12 holders.
- The largest Novo Nordisk buyer in Q3 2016 was Loomis, Sayles & Company, an estimated $165M added.
- The largest Novo Nordisk seller in Q3 2016 was Jennison Associates, an estimated $545M sold.
Based on aggregated 13F filings for Q3 2016.